[Houston]....Enbrel [etanercept], a tumor necrosis factor-alpha [TNF-a] inhibitor, relieves the clinical symptoms of psoriasis, it may also clear up the depression and fatigue common among those with this disease…
In a double-blind placebo-controlled phase III trial, 55% of patients taking Enbrel had significant reductions from baseline in symptoms of depression after 12 weeks of therapy, found Stephen Tyring, M.D., of the University of Texas Health Science Center here, and colleagues.
This compared with 39% of patients taking a placebo, they reported in a study published online today by The Lancet.
Enbrel is approved by the FDA for treating symptoms of psoriasis as well as psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis. Depression and fatigue are common among psoriasis patients, the researchers noted, and are probably due in part to the altered appearance of the skin and by joint pain in those who also have psoriatic arthritis. . [MED PAGE TODAY]
No comments:
Post a Comment